ADVAITE Receives CE Mark Clearance For Its RapCov(TM) Rapid COVID-19 Test

Company's diagnostic testing kit "RapCov(TM)" offers the promise of a convenient and rapid solution for screening large populations for IgG antibodies to COVID-19

MALVERN, Penn., Dec. 4, 2020 /PRNewswire/ -- ADVAITE Inc., an innovative biotech company focused on developing novel diagnostic point-of-care tests, announced today it has received CE Mark clearance for its COVID-19 rapid response IgG antibody test, RapCov(TM), to help efforts to contain the spread of coronavirus infection.

https://mma.prnewswire.com/media/1123428/Advaite_Logo.jpg [https://mma.prnewswire.com/media/1123428/Advaite_Logo.jpg ]

The CE Mark clearance will help strengthen Europe's public health protections against biological threats by facilitating the availability and use of medical countermeasures, such as the ADVAITE RapCov(TM) Rapid COVID-19 Test, which are needed during public health emergencies. ADVAITE is committed to supplying the global market with its COVID-19 rapid response diagnostic testing kits. ADVAITE Inc. in partnership with OBELIS S.A as an authorized representative, will begin expansion and marketing efforts immediately.

"We feel the ADVAITE RapCov(TM) Rapid COVID-19 Test may offer unique advantages in containing the disease. It is simple to use, can provide accurate results from a drop of fingertip blood and detect IgG antibodies to the COVID-19 virus, and show results in 15 minutes," said Karthik Musunuri, Chief Executive Officer of Advaite. "Further, blood specimens do not need to be sent to a laboratory which makes this an ideal solution for screening mass populations."

About ADVAITE Inc.

ADVAITE Inc. is a Malvern, PA headquartered biotech company focused on developing novel therapeutics and diagnostics to help patients suffering from a variety of debilitating diseases. The word 'Advaite' means 'one without a second', unrivaled or unique. At ADVAITE, we aspire to be just that.

Currently, ADVAITE Inc. is focused on developing novel point-of-care assays to help combat the modern world's deadliest disease, COVID-19. With a new high complexity CLIA laboratory based in Chicago, Illinois and an expanded state-of the-art R&D facility in Malvern, PA; ADVAITE is continuously innovating, developing and commercializing point-of-care tests to address this pandemic and help impact large populations.

About the ADVAITE RapCov(TM) Rapid COVID-19 Test

The ADVAITE RapCov(TM) Rapid COVID-19 Test is a lateral flow immunochromatographic assay for the presumptive qualitative detection of IgG antibodies to the COVID-19 virus in human whole blood fingerstick samples. In a US based Point-of-Care clinical study at multiple sites, the RapCov(TM) Rapid COVID-19 test exhibited 90% sensitivity and 100% specificity on over 100 subjects in regards to the detection of the presence of IgG COVID-19 antibodies in fingerstick whole blood.

Contacts

For Sales Inquires Brahma Prathi Director of Commercial Operations, Advaite Inc. bprathi@advaite.com [mailto:bprathi@advaite.com]

European Authorized Representative OBELIS S.A. Bd Général Wahis, 53 B-1030 Brussels Belgium Tel: +3227325954 Fax: +3227326003 mail@obelis.net [mailto:mail@obelis.net]

Logo - https://mma.prnewswire.com/media/1123428/Advaite_Logo.jpg [https://c212.net/c/link/?t=0&l=en&o=3002465-1&h=1299409164&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1123428%2FAdvaite_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1123428%2FAdvaite_Logo.jpg]